Alphyn Secures FDA Clearance of Investigational New Drug Application for Atopic Dermatitis Treatment
Alphyn Secures FDA Clearance of Investigational New Drug Application for Atopic Dermatitis Treatment NEWS PROVIDED BY Alphyn Biologics Feb 19, 2025, 07:30 ET Zabalafin Hydrogel holds potential for first comprehensive AD treatment with safety and patient tolerability profile for long-term, worry-free, continuous use ANNAPOLIS, Md., Feb. 19, 2025 /PRNewswire/ — Alphyn, a clinical-stage dermatology company…